FDA probes Novo Nordisk over drug safety reporting lapses

Novo Nordisk under fire as FDA flags drug safety reporting failures

Danish Weight-Loss Injection Maker Novo Nordisk Faces Criticism and Competition

With key patents expiring, Novo Nordisk—the Danish pharmaceutical giant behind blockbuster diabetes and weight-loss drugs—is now confronting regulatory scrutiny and the looming threat of cheaper generic competitors, developments that could soon ripple into Switzerland as well.

FDA Reprimands Novo Nordisk Over Reporting Failures

Novo Nordisk produces widely used medications like Ozempic and Wegovy, injectable drugs for diabetes and weight loss. In the U.S., the company is now under fire from the Food and Drug Administration (FDA) for allegedly failing to properly report potential side effects.

Following an inspection, the FDA identified several violations of mandatory reporting requirements:

After taking the weight-loss drug liraglutide, one patient suffered a stroke resulting in permanent disability. Although the individual claimed the drug was not to blame, U.S. regulations require all such adverse events to be reported—regardless of whether a causal link is established.
Novo Nordisk also failed to adequately document the death of a patient using semaglutide, the active ingredient in Ozempic and Wegovy. The company dismissed the case as "invalid" because the patient's identity could not be definitively verified. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.
The FDA further accused Novo Nordisk of insufficient follow-up on reports of serious incidents. In one case, a patient developed suicidal thoughts after taking semaglutide; in another, a patient died by suicide. According to the agency, the company should have promptly investigated these cases—including gathering additional details, such as any preexisting mental health conditions.

Both the U.S. and Switzerland enforce strict pharmacovigilance rules, requiring manufacturers to report potential side effects even after a drug's approval. While the FDA has not established a direct link between Ozempic and the reported deaths, its criticism centers on Novo Nordisk's incomplete compliance with reporting obligations. The agency expressed concerns about whether the company is "capable of adequately monitoring the safety of its products." For now, Swissmedic, Switzerland's drug regulatory authority, sees no immediate need for action, as reported by the Tages-Anzeiger.

Surge of Low-Cost Alternatives on the Horizon

Novo Nordisk's dominance is set to face a challenge: the patents for semaglutide are expiring, paving the way for generic drugmakers to produce lower-cost versions. Generics typically undercut brand-name prices dramatically, as they bypass the high costs of research and development. In Switzerland, a monthly supply of Ozempic currently retails for 106 Swiss francs.

India, the world's largest generic drug manufacturer, is gearing up to capitalize on the patent cliff. Industry analysts anticipate a rapid influx of semaglutide copycat drugs once the patent expires—a pattern consistent with India's aggressive generic production strategies. A case in point is sitagliptin, a diabetes medication (not used for weight loss) whose patent expired in 2022. Within a month, nearly 30 generic versions hit the market; a year later, the number had ballooned to nearly 100.

The downside? Wider availability at lower prices could lead to misuse—such as cosmetic weight loss without medical supervision. Compounding the risk, these drugs can be ordered directly from abroad into Switzerland without Swissmedic approval or oversight.

As the debate over access, safety, and regulation intensifies, these medications are poised to remain a contentious topic in the months and years ahead.